Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (March 2018)
57 slides from Anavex Life Sciences's investor presentation, March 2018

Slide 1: March 2018 Corporate Presentation
March 2018 Corporate Presentation Christopher U Missling, PhD President & CEO Nasdaq: AVXL

Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “b

Slide 3: Novel Target, New Approach to Treating CNS
Novel Target, New Approach to Treating CNS Anavex utilizes precision genetic medicine to treat severe, often devastating, neurological disorders ranging from rare diseases such as Rett syndrome to large indications like Alzheimer’s disease 3

Slide 4: Summary
Summary Focus Finding effective treatments for neurodevelopmental and neurodegenerative diseases, areas of high unmet need Mechanism Sigma-1 Receptor (S1R) targeting cellular homeostasis Approach Applying precision medicine to CNS ANAVEX®2-73, orally available S1R agonist with strong IP (COM 2033) a

Slide 5: Identification of Gene Signature from ANAVEX 2-73 Patients
Identification of Gene “Signature” from ANAVEX®2-73 Patients ANAVEX®2-73 Phase 2a clinical trial Corresponding approach to ANAVEX®2-73 treatment oncology precision medicine NOW: Genetic signatures of the strongest responders to ANAVEX®2-73 5

Slide 6: Portfolio of Compounds Varying in Sigma-1 Receptor Binding Activities
Portfolio of Compounds Varying in Sigma-1 Receptor Binding Activities CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 *RETT SYNDROME ANAVEX®2-73 ALZHEIMER’S DISEASE PARKINSON’S DISEASE *INFANTILE SPASMS FRAGILE X ANGELMAN’S *FRONT. DEMENTIA (FTD) ANAVEX®3-71 (AF710B) ALZHEIMER’S DISEASE PARKINSON’S DI

Slide 7: Novel Target: Sigma-1 Receptor
Novel Target: Sigma-1 Receptor Su et al., Trends Pharmacol Sci. 2016 7

Slide 8: ANAVEX 2-73 is a S1R Agonist and Activates the Sigma-1 Receptor
ANAVEX®2-73 is a S1R Agonist and Activates the Sigma-1 Receptor S1R is an integral membrane protein involved in cellular homeostasis which targets restoration of neuroplasticity and cellular stress response2,3 S1R deficiency accelerates Endogenous S1R agonists activate the Sigma-1 Receptor in situat

Slide 9: Overview ANAVEX 2-73 Clinical Trials
Overview ANAVEX®2-73 Clinical Trials ANAVEX®2-73-001 Study: • Randomized, double-blind, placebo- Population PK, i.e. non- controlled Phase 1 (oral) linear mixed effect • Single ascending dose (SAD) (NLME) modeling, non- • 22 healthy subjects compartmental analysis and formal concept analysis (FCA) A

Slide 10: Using Precision Medicine to Increase Clinical Trial Success Rate
Using Precision Medicine to Increase Clinical Trial Success Rate +38% +64% Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis 10

Slide 11: Rett Syndrome (RTT): A Devastating Monogenic Disorder
Rett Syndrome (RTT): A Devastating Monogenic Disorder Rare genetic postnatal progressive neurodevelopmental disorder ▪ Rett syndrome (RTT) is caused by spontaneous (de novo) mutation in the MECP2 gene located on the X chromosome ▪ For males the gene mutation is lethal since males have only one X chr

Slide 12: MECP2 is Mutated in Rett Syndrome Leading to Loss of Neuronal Function
MECP2 is Mutated in Rett Syndrome Leading to Loss of Neuronal Function and Loss of BDNF ▪ MECP2 is a calcium dependent gene, affects dendritic spine development and necessary for other gene expressions, including BDNF ▪ Loss of MECP2 function alters excitatory/inhibitory synaptic balance ▪ MECP2 fun

Slide 13: ANAVEX 2-73 Regulates Gene Expression and Restores BDNF Levels
ANAVEX®2-73 Regulates Gene Expression and Restores BDNF Levels p<0.05 ANAVEX®2-73 fully restores BDNF expression levels in the hippocampus in the Fmr1 KO mouse model (p<0.05, KO vehicle vs. KO ANAVEX®2-73) Presented at Antiepileptic Drug Trials XIV 2017 Conference 13

Slide 14: ANAVEX 2-73 Significantly Reduces Impairment in Mutated MECP2 Rett Mouse Model
ANAVEX®2-73 Significantly Reduces Impairment in Mutated MECP2 Rett Syndrome Mouse Model Clasping at 8 weeks 100 90 p<0.001 80 Normal Impaired *** Clasping Hindlimbs (%) 70 60 50 p<0.05 40 * 30 20 10 0 Mecp2_WT Vehicle Mecp2_HET Vehicle Mecp2_HET AV2-73 (10 mg/kg) Mecp2_HET AV2-73 (30 mg/kg) 100 Clas

Slide 15: Significant Improvement in Multiple Movement Impairments
Significant Improvement in Multiple Movement Impairments Rotarod Neurocube Startle Motor Coordination and exercise Platform that employs computer Wild type (WT) mice have a capacity are assessed: vision to detect changes in gait higher startle response compared ANAVEX®2-73 treated mice took geometry

Slide 16: ANAVEX 2-73 Phase 2 Rett Syndrome Study Design
ANAVEX®2-73 Phase 2 Rett Syndrome Study Design Randomized, Double-Blind, Placebo-Controlled Study of ANAVEX®2-73 4 weeks 4 weeks 8 weeks Baseline Dose Titration Full Dose Observation Treatment AV 2-73: AV 2-73: Low dose Low dose 12 Weeks Initial N<90 Randomization to 1 of 3 arms AV 2-73: AV 2-73: Vo

Slide 17: ANAVEX 2-73-003 Alzheimer's Study: Continued Safety and Tolerability through 109 weeks
ANAVEX®2-73-003 Alzheimer’s Disease Study: Continued Favorable Safety and Tolerability through 109 weeks PART A PART B 003 Study## 002 Study# 002 Study# 1. Estimate the maximal tolerated 1. Establish continued safety Establish continued safety and dose (MTD) and tolerability of ANAVEX tolerability o

Slide 18: Primary and Secondary Endpoints Met in Phase 2a Alzheimer's Trial
ANAVEX®2-73 Primary and Secondary Endpoints Met in Phase 2a Clinical Trial of Mild-to-Moderate Alzheimer’s Patients ▪ Phase 2a results demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile at doses between 10mg and 50mg of oral daily ANAVEX®2-73 ▪ Primary

Slide 19: ANAVEX 2-73 Primary Endpoint Safety Data
ANAVEX®2-73 Primary Endpoint Safety Data measured to 57 weeks: ▪ The most common adverse event (AE): mild dizziness ▪ When patients were first dosed with highest dose ▪ Was transient and reversible ▪ Consistent with Blood Brain Barrier (BBB) penetration ▪ 98% of all AEs were mild or moderate and rev

Slide 20: Secondary Endpoints: High Concentration Linked to Improved Response
Secondary Endpoints: High ANAVEX®2-73 Concentration linked to Consistent Improved Response Across All Analytes and Periods ANAVEX®2-73 shows a consistent response across the 3 different times frames: Part A1 [0-24h] Part A2 [24-264h] Part B [52 weeks] Immediate response Short-term response Long-term

Slide 21: Robust Dose/Response Effect of ANAVEX 2-73
Robust Dose(Concentration)/Response Effect of ANAVEX®2-73 Systematic exploration of the full data matrix using KEM® demonstrates consistent concentration-response relationship for 6 main exploratory endpoints: cognition, function and biomarker (MMSE, ADCS-ADL, EEG/ERPs) 54% High dose -> Improved res

Slide 22: Relation between ANAVEX 2-73 Concentration and MMSE
Relation between ANAVEX®2-73 Concentration and MMSE An increase of MMSE during 57 weeks is a rare event. A patient receiving a higher concentration of ANAVEX2-73 has a 2.1-fold chance of improving its MMSE Low Medium High High Concentration MMSE increases Increasing Decreasing Low Concentration MMSE

Slide 23: Relation between ANAVEX 2-73 Concentration and ADCS-ADL
Relation between ANAVEX®2-73 Concentration and ADCS-ADL An increase of ADCS-ADL during 57 weeks is a rare event. A patient receiving a higher concentration of ANAVEX2-73 has a 1.6-fold chance of improving its ADCS-ADL Low Medium High High Concentration ADCS-ADL increases High Medium Low Low Concentr

Slide 24: Patient Cohort with Cognitive and Functional Improvements
Patient Cohort with Cognitive and Functional Improvements at 57 Weeks: RetainedMMSE Response at 109 and ADCS-ADL Weeks remained steady over 27 months (109 weeks) 30 28 26 24 101009 22 MMSE 101011 20 101013 18 101014 16 102006 14 102010 12 10 0 5 17 31 41 53 57 70 83 96 109 Weeks 80 75 70 65 101009 A

Slide 25: MMSE and ADCS-ADL Significantly Different to SoC AD
MMSE Δ and ADCS-ADL Δ Significantly Different to SoC AD 1.8 MMSE points difference 4 ADCS-ADL points difference 1.8 MMSE points 4 ADCS-ADL points improvement to historical improvement to historical control (SoC)# at week 57 control (SoC)# at week 57 (p=0.0164) (p=0.0186) ▪ Comparison to historical c

Slide 26: Summary
Summary ▪ ANAVEX®2-73 appears to have a favorable safety profile and to be generally well tolerated ▪ ANAVEX®2-73 has demonstrated efficacy in the clinic as well as in multiple preclinical disease models validating the Sigma-1R mechanism of action ▪ Genetic Signatures for those who respond best to A

Slide 27: Financial Position and Near Term Catalysts
Financial Position and Near Term Catalysts ▪ Cash (as of December 31, 2017): $28.0M; No debt ▪ The company is well capitalized to achieve clinical readouts Orphan Drug Designations granted for the following indications: Rett syndrome, Infantile spasms and Frontotemporal dementia Phase 2a – Repor

Slide 28: Anavex Life Sciences Expertise
Anavex Life Sciences Expertise Management Team ChristopherU. Missling, Emmanuel O Fadiran, Stephan Toutain, TasosZografidis, Daniel Klamer, PhD RPh, PhD MS, MBA MS, PhD PhD President& CEO SVPof RegulatoryAffairs SVPof Operations VP of ClinicalOperations VP of Business Development & Scientific Strate

Slide 29: Contact Us
Contact Us Corporate Office: Shareholder & Media Relations: Anavex™ Life Sciences Corp. Clayton Robertson 51 West 52nd Street, 7th floor The Trout Group New York, NY 10019 (646) 378-2900 1-844-689-3939 crobertson@troutgroup.com www.anavex.com NASDAQ: AVXL ANAVEX is a trademark of Anavex Life Science

Slide 30: Back Up Slides
Back Up Slides Woenavex »

Slide 31: Comprehensive Phase 2a Patient Characterization
Comprehensive Phase 2a Patient Characterization to Identify Actionable Phase 2/3 Clinical Trial Parameters MMSE ADCS-ADL COGSTATE MMSE EEG/ERP Scores ADCS-ADL HAM-D Baseline COGSTATE Scores EEG/ERP Population PK HAM-D Evolution == Clinical DNA RNA Gut assessment, FGS FGS Microbiota Vital signs, co-m

Slide 32: Example of a Gene Signature: BDNF Polymorphism Val66met
Example of a Gene “Signature”: BDNF Polymorphism Val66met BDNF Val66met Polymorphism implicated in Neurodevelopmental and Neurodegenerative Disorders BDNF Val66met polymorphism directly correlates with: 1/3 of all patients have this mutation Higher seizure frequency Accelerated cognitive decline and

Slide 33: Targeted Genomic-Driven Clinical Trial Approach in Alzheimer's Disease
Example of a Targeted Genomic-Driven Clinical Trial Approach in Alzheimer’s Disease Boots EA et al., Neurology. 2017 May 30;88(22):2098-210 33 Brookmeyera R et al., Alzheimer’s & Dementia. 2017 in press

Slide 34: Patient Genomic Analysis - Genetic Mutations Linked to Alzheimer's
Patient Genomic Analysis - Number of Associated Genetic Mutations Linked to Alzheimer’s Disease have Increased GWAS = genome-wide association studies Contribution of gene variants to the development of Alzheimer's disease has clinical implications, including enhancing diagnostic accuracy and providi

Slide 35: Rare Disease Drug Discovery Approach: Higher Success Rate Expected
Rare Disease Drug Discovery Approach: Higher Success Rate of Clinical Trials Expected 35

Slide 36: Shift to Use Precision Medicine in Alzheimer's
Shift to Use Precision Medicine to Break the Notion That Alzheimer’s is a Single Disease ▪ Researchers are starting to combine genetics with lessons learned from the failed β amyloid-based clinical trials, not only to find new targets but also to stratify patients ▪ The view now is that the disease

Slide 37: Examples of Continued Improvements and Reported Events
Examples of Continued Improvements and Reported Events ‘Therapeutic Response’ during 57 Weeks PATIENT EVENTS: THERAPEUTIC RESPONSE UNEXPECTED 101001 MORE ALERT REGARDING SURROUNDINGS Examples of MMSE "Strong" Patient 101002 FEELS MUCH HAPPIER MAKING JOKES Responders 101003 MUCH HAPPIER WHEN ATTENDIN

Slide 38: HAM-D: Reduction of Insomnia, Anxiety and other Symptoms
HAM-D: Reduction of Insomnia, Anxiety and other Symptoms Improved Items of HAM-D Scored Improvement Count in [%] Insomnia 8 29% Work and activities 6 21% Anxiety (psychic and somatic) 5 18% Agitation 4 14% Depressed 4 14% Insight 3 11% Hypochondriasis 2 7% Loss of libido or other genital symptoms 2

Slide 39: Robust Correlation of Cognition, Function and Behavior Response
ANAVEX®2-73: Robust Correlation of Cognition, Function and Behavior Response ANAVEX®2-73 Response cluster in a homogenous manner: Consistent response across multiple domains ▪ Principal component analysis of the Δ sub-scores between week 31 and baseline for MMSE (MM), ADCS-ADL (AD), and HAM-D (HA) G

Slide 40: ANAVEX 2-73 Rescues Synaptic Networks
ANAVEX®2-73 Rescues Synaptic Networks and has Positive Effect on Cognition and Behavior 1. ERP peak measures (P300): fundamental measures of synaptic network performance 2. ERP target detection task measures: direct measures of attention, speed of brain processing, and simple behavioral ADCS-ADL: Be

Slide 41: Comprehensive Pre-Specified PK Sampling Protocol during Phase 2a
Comprehensive Pre-Specified PK Sampling Protocol during Phase 2a Study Part A: IV (3/5 mg), Oral (30/50 mg) Part B: Oral (10 to 50 mg) Measures (hours) 012 68 12 18 24 012 68 12 18 24 48 72 120 192 264 48 72 120 192 264 Daily intake Period 1 Wash out Period 2 Part B: All patients on ANAVEX®2-73 oral

Slide 42: Clearance of ANAVEX 2-73 Independent of given Dose
Clearance of ANAVEX®2-73 Independent of given Dose Total average drug exposure over time AUC(0 to infinity) Area Under the Curve, 0-24h ANAVEX2-73 Treatment 42

Slide 43: Confirmed Reliable Inter-Individual Variability for Phase 2a Study
Confirmed Reliable Inter-Individual Variability (Dispersion) for the ANAVEX2-73 Phase 2a Study with 32 Patient Cohort Real data -8 -8.5 ▪ Evaluation of the dispersion -9 -9.5 index of all the 32 patient of the Phase 2a reveals that Dispersion index -10 -10.5 above any random sample of -11.5 -11 16 p

Slide 44: Alzheimer Disease Progression: Open-label vs Placebo-controlled Studies
Alzheimer Disease Progression: Comparable cognitive decline in open-label studies as in placebo-controlled studies Progressive decline in cognition: Progressive decline in cognition: Open-label study with SoC# Double-blind placebo-controlled study with SoC## ADAS-Cog Change from baseline 52 weeks Pl

Slide 45: ANAVEX 2-73: Dose-Dependent Anti-Seizure Effects
ANAVEX®2-73: Dose-Dependent Anti-Seizure Effects Significant Seizure Reduction with ANAVEX®2-73 in Angelman Seizure Model ANAVEX 2-73 (10 mg/kg ip dosed daily for 14 days) Significant Seizure Reduction with ANAVEX®2-73 in both MES and PTZ-Induced Seizure Models 100 p=0.0065 90 80 MES-induced convuls

Slide 46: Parkinson's Disease Model: Significantly Improves Motor Behaviors
Parkinson’s Disease Model: ANAVEX®2-73 Significantly Improves Motor Behaviors ▪ ANAVEX®2-73 was evaluated in the 6-OHDA Parkinson’s disease model ▪ ANAVEX®2-73 significantly improves motor behaviors compare to a double- blind control group (saline) ▪ (A) Spontaneous rotation activity ▪ (B) Cylinder

Slide 47: ANAVEX 2-73 Normalizes Pathophysiological Biomarkers
ANAVEX®2-73 Normalizes Pathophysiological Biomarkers ANAVEX®2-73 reduces microglia over-activation ANAVEX®2-73 restores dopaminergic neurons ANAVEX®2-73 significantly decreased the expression of ANAVEX®2-73 significantly increases tyrosine- CD68 (marker of activated microglia) in the substantia hydr

Slide 48: Positive Preclinical Data in Parkinson's Disease
Positive Preclinical Data in Parkinson’s Disease ✓ At all doses tested ANAVEX®2-73 reduced novelty/stress-induced activity while basal activity levels were not significantly affected ✓ Mouse behavioral and motor patterns were completely normal; no signs of dystonia or stereotypic behaviors were obse

Slide 49: Sigma-1 Receptor Activation and Neurodegenerative Diseases
Sigma-1 Receptor Activation and Neurodegenerative Diseases 49

Slide 50: Confirmed Effects of Sigma-1 Receptor Activation
Confirmed Effects of Sigma-1 Receptor Activation … ✓ Synaptogenesis ✓ Restores Ca2+ imbalance ✓ Reduces Inflammation ✓ Reduces Oxidative stress ✓ Reduces Tau hyper-phosporylation ✓ Restores Mitochondrial dysfuncion ✓ Reduces Protein Misfolding … effects relevant in both neurodevelopmental as well as

Slide 51: Sigma-1R Agonists MoA: Restoring Homeostasis
Sigma-1R Agonists MoA: Restoring Homeostasis ANAVEX®2-73 Sigma-1R helping / Restoring Homeostasis stimulating own body to regain functionality Su et al., Trends Pharmacol Sci. 2016 Villard et al., J. Psychopharmacol. 2011 [σ1 Antagonist] Source: Adapted from Miki et al, Dec 9. doi: 10.1111/neup.1208

Slide 52: ER-Mitochondria Axis Disruption; Sigma-1R Restores Association
Common in both Neurodegenerative & Neurodevelopmental Diseases: ER-Mitochondria Axis Disruption … Sigma-1R Restores Association … Normal condition Disease condition S1R ANAVEX®2-73 Miller et al. Trends Neurosci., 2016; Lahmy et al. Neuropsychopharmacol., 2013 Normally quiescent S1Rs become activated

Slide 53: ANAVEX 3-71 Decreases Hallmark Pathologies in Alzheimer's Model
ANAVEX®3-71 Significantly Decreases Hallmark Pathologies in 3xTg-Alzheimer’s Disease Model ▪ 10 month-old 3xTg-AD and WT mice ▪ administered i.p. with tap water or ANAVEX®3-71 (10 mcg/kg/day) for 2 months 53 Source: Fisher et al., Neurodegenerative Diseases 2015 DOI: 10.1159/000440864

Slide 54: Sigma-1R Represents a Functional Connection Between Cell Body and DNA
Sigma-1R Represents a Functional Connection Between the Cell Body and the DNA Sigma-1R Active in the Cell Body The Sigma-1R is mainly expressed in the cell body at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) Mouse retinal ganglion cell illuminated by Thy-1 driven GFP; immun

Slide 55: Pathological GSK-3β Activation can be Inhibited with ANAVEX 2-73
Pathological GSK-3β Activation can be Inhibited with ANAVEX®2-73 Lahmy et al., Neuropsychopharmacol., 2013 Active GSK-3β has been found in AD brains with neurofibrillary changes and an increase in tau hyperphosphorylation, neurodegeneration and spatial Injection of Aβ25-35 yields a hyper-inflammator

Slide 56: Sources: GlobalGenes.org, PhRMA, NIBR
Sources: GlobalGenes.org1, PhRMA, NIBR 5656

Slide 57: Neurodegenerative Diseases
NEURODEGENERATIVE DISEASES The global cost of dementia is estimated to be US$ 818 billion More than 10 Million people are believed to have Parkinson's disease Economic burden of Alzheimer's disease (AD) care is estimated to reach $1.5 trillion by 2050 FDA has approved 4 drugs for AD that only tempor
Source: Internet Archive copy of anavex.com
More decks from Anavex Life Sciences Corp.
Proxy Contest (September 2026)25 slides · September 2026
AD/PD 2026, Copenhagen27 slides · Mar 21, 2026
Investor Presentation (February 2026)37 slides · February 2026
Investor Presentation (January 2026)37 slides · January 2026
Technical Presentation (February 2022)24 slides · Feb 2, 2022
Investor Presentation (September 2021)43 slides · Sep 13, 2021